PBLS
SinkerParabilis Medicines, Inc. · Healthcare · United States · $3.4B cap · $27.2M/day traded
$27.44 -0.7% · close 20 Nov · scored 21 Nov
Sinker: Weak business, rich price and weak momentum. Nothing here to keep it afloat.
As of 21 Nov 2026, the MoatMap Score for Parabilis Medicines, Inc. (PBLS) is 4/100, ranked against 25,000+ stocks in 38 markets (Quality 18, Value 24, Momentum 27, each scored against its sector).
Does the score work? Each tenth of the ranking, tracked monthly. See the record →
ABOUT PARABILIS MEDICINES, INC.
Read
Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment.
FINANCIAL SUMMARY (USD)
| Year | 2024 | 2025 | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|
| Income and shares | ||||||
| Revenue | — | — | — | 3.4M | 4.0M | — |
| Net margin | n/m | n/m | — | — | — | — |
| EPS | -2.0 | -1.8 | -3.6 | -2.6 | -2.4 | — |
| Share count | 118.1M | 118.1M | 123.7M | — | — | — |
| Balance sheet | ||||||
| Debt | 66.2M | 58.7M | 41.8M | — | — | — |
| Equity | 56.4M | -16.5M | — | — | — | — |
| Debt/equity | 1.2x | n/m | — | — | — | — |
| Cash flow | ||||||
| Op. cash flow | -103.6M | -123.7M | -120.8M | — | — | — |
| Cash flow margin | n/m | n/m | — | — | — | — |
| Investing CF | 30.2M | 39.8M | — | — | — | — |
| Financing CF | 78.1M | 64.4M | — | — | — | — |
Cash on hand equals about 7.2 years of the operating cash used in the last twelve months. Spending on equipment or exploration and any new funding are not counted.
Not enough steady price history for a read yet.
How this is worked out
The Price check reads only the chart, the price side of the Momentum score in words; it is not the MoatMap Score.
- Still falling: It set a new 52-week low in the last two weeks, after a deep fall.
- Finding a floor: It fell hard, but has set no new low for more than two weeks.
- Turning up: It has climbed off its low and is back above a rising 50-day average.
- In an uptrend: It is near its 52-week high and above its 200-day average.
- No clear trend: None of the above: no recent deep fall and no steady climb.
- No read yet (this stock): Not enough price history yet: it needs a year of trading.
In past US falls, waiting for Turning up cut the chance of another 20% drop from 42% to 33%. Returns were no better, and 33% of turns failed.
The exact rules
Still falling is a new 52-week low in the last two weeks, at least 25% below the high, with the low set after the high. Finding a floor is the same fall with no new low in the last two weeks. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average, with the 50-day average above the 200-day, and within 15% of the high. No clear trend is everything else. No read yet is under 252 trading days of history, or missing data. A new state shows once it has held for three trading days.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PBLS are excluded.
| Ticker | Company | Mkt Cap | Score |
|---|---|---|---|
| PBLS | Parabilis Medicines, Inc.(you) | $3.4B | 4 |
| VKTX | Viking Therapeutics, Inc. | $3.2B | 7 |
| IONS | Ionis Pharmaceuticals, Inc. | $4.4B | 2 |
| DYN | Dyne Therapeutics, Inc. | $2.9B | 11 |
| RCUS | Arcus Biosciences, Inc. | $2.2B | 6 |
| COGT | Cogent Biosciences, Inc. | $4.6B | 9 |
| CELC | Celcuity Inc. | $2.6B | 9 |
| TNGX | Tango Therapeutics, Inc. | $3.7B | 16 |
| BEAM | Beam Therapeutics Inc. | $2.2B | 9 |
| VERA | Vera Therapeutics, Inc. | $1.8B | 7 |
Peer medians: ROE -30.1% · P/E 25.6x · Gross margin 63.4%
Company Deep Dive
A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.